Pharmafile Logo
Pharmafocus logo
Advanced Search

AbbVie

Showing 15 posts of 222 posts found.

fdaoutsideweb

FDA rejects Allergan’s Abicipar pegol for neovascular age-related macular degeneration over benefit/risk concerns

June 29, 2020
Sales and Marketing AbbVie, Allergan, FDA, pharma

The FDA has moved to reject Allergan’s vascular endothelial growth factor (VEGF) factor A inhibitor, Abicipar pegol, as treatment for …

News
mr_robot_cancer

AbbVie’s Venclexta plus azacitidine shows improved survival and remissions rates in leukaemia patients

June 15, 2020
Sales and Marketing AbbVie, leukaemia

AbbVie have announced positive results from its latest Phase 3 clinical trial where Venclexta plus azacitidine improved survival and remission …

News
shutterstock_273326141

AbbVie and Genmab sign drug development and commercialisation deal worth up to $4bn

June 11, 2020
Research and Development AbbVie, Genmab, partnership, pharma

AbbVie has joined forces with Genmab to develop and commercialise three of the latter’s early-stage Genmab drug products – epcoritamab …

News
shutterstock_273326141

$63bn Allergan/AbbVie merger review could be delayed by coronavirus

March 18, 2020
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Allergan, merger, pharma

The $63 billion merger of major pharma players AbbVie and Allergan could be facing hurdles on the road to regulatory …

News

Venclyxto combo scores European approval for previously untreated chronic lymphocytic leukaemia

March 13, 2020
Medical Communications, Sales and Marketing AbbVie, European Commission, Roche, Venclyxto, pharma

The European Commission has moved to authorise AbbVie and Roche’s B-cell lymphoma-2 (BCL-2) inhibitor Venclyxto (venetoclax) when used in combination …

News
abbvie_0

AbbVie’s Rinvoq hits target in psoriatic arthritis sub-population at Phase 3

February 6, 2020
Research and Development AbbVie, Rinvoq, pharma, psoriatic arthritis

AbbVie has unveiled new Phase 3 data on its selective and reversible JAK inhibitor Rinvoq (upadacitinib) in the treatment of …

News
abbvie_0

AbbVie’s Venclyxto pins down CHMP approval for treatment-naive chronic lymphocytic leukaemia

February 3, 2020
Sales and Marketing AbbVie, CHMP, EMA, Venclyxto, pharma

The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) has awarded recommendation to AbbVie’s Venclyxto (venetoclax), …

News
abbvie_0

AbbVie’s Skyrizi outpaces Novartis’ Cosentyx in plaque psoriasis skin clearance

January 16, 2020
Research and Development AbbVie, Cosentyx, Novartis, Skyrizi, pharma, psoriasis

AbbVie has made it known that Skyrizi (risankizumab) outpaced Novartis’ Cosentyx (secukinumab) at Phase 3 in the treatment of plaque …

News
abbvie_0

AbbVie granted EU marketing authorisation for new arthritis drug

December 19, 2019
Business Services AbbVie, EC, EU, arthritis, rheumatoid arthritis

AbbVie have announced that the European Commission (EC) have granted marketing authorisation for RINVOQ (upadacitnib). It’s a daily selective reversible …

News
abbvie_0

Strong four-year follow-up data revealed for AbbVie’s venetoclax combo in chronic lymphocytic leukaemia

December 9, 2019
Research and Development, Sales and Marketing ASH 2019, AbbVie, chronic lymphocytic leukaemia, pharma, venetoclax

AbbVie used the platform of the American Society of Hematology (ASH) conference to present four-year follow-up analysis data on venetoclax …

News
shutterstock_79370437

New ICER report reveals most cost-effective rheumatoid arthritis therapies

November 27, 2019
Research and Development, Sales and Marketing AbbVie, Eli Lilly, Humira, Olumiant, Pfizer, Rinvoq, Xeljanz, pharma

The Institute for Clinical and Economic Review (ICER) has unveiled a new report comparing the clinical efficacy and cost-effectiveness of …

News
humira_abbott__4

International revenue for world’s best-selling drug Humira falls 33.5% in the face of biosimilar competition

November 4, 2019
Sales and Marketing AbbVie, Humira, pharma

With the release of its Q3 financial results, AbbVie confirmed that international revenues for its blockbuster therapy Humira (adalimumab) – …

News
abbvie_0

AbbVie’s Rinvoq impresses at Phase 3 in active psoriatic arthritis sub-population

October 31, 2019
Research and Development AbbVie, Rinvoq, pharma

AbbVie has unveiled new Phase 3 data on two doses of its JAK inhibitor Rinvoq (upadacitinib), showing that the therapy …

News
takeda_deerfield_hq

Takeda’s Entyvio outperforms AbbVie’s Humira in moderate-to-severe ulcerative colitis

September 27, 2019
Medical Communications, Research and Development AbbVie, Entyvio, Humira, Takeda, pharma, ulcerative colitis

Takeda has released strong new data for Entyvio (vedolizumab), showing that the gut-selective biologic outperformed AbbVie’s blockbuster anti-tumour necrosis factor-alpha …

News
abbvie_0

AbbVie’s Mavyret scores FDA label expansion to shorten treatment duration for hepatitis C patients

September 27, 2019
Medical Communications, Sales and Marketing AbbVie, FDA, hepatitis, hepatitis C, mavyret, pharma

The FDA has chosen to expand the existing label for AbbVie’s Mavyret (glecaprevir/pibrentasvir), it has been revealed, to include the …

News

Latest content

Regeneron shares data for multiple myeloma treatment

December 8, 2023

Merck collaborates with Acceleration Consortium for AI experimentation

December 8, 2023

AbbVie to acquire Cerevel Therapeutics for approximately $8.7bn

December 7, 2023

ONK Therapeutics and NAYA Biosciences enter partnership for NK cell therapy development

December 7, 2023

FDA approves Novartis’ Fabhalta for PNH treatment

December 6, 2023